KRAS and pancreatic neoplasm: By multiple-genomics data mining we found that the KRAS G12D mutation was significantly associated with the survival of pancreatic patients and identified 4 genes that are associated with KRAS G12D mutation and highly expressed in pancreatic cancer and could regarded as promising targets for the pancreatic cancer therapy.